FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel ...

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

The campaign aims to reduce the spread of hereditary blood disorders such as sickle cell anaemia and beta-thalassemia ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Few fields in medicine are as promising and complex as gene therapy. As researchers race to develop cures for previously ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...